21
Seiji Yoshikawa, Eita Emori, Eumiyoshi Matsuura, Richard Clark, Hironori Ikuta, Kazunobu Kira, Nobuyuki Yasuda, Tadashi Nagakura, Kazuto Yamazaki: Novel condensed imidazole derivatives. Townsend And Townsend And Crew, May 11, 2006: US20060100199-A1

The present invention is related to compounds represented by the following formula, or salts or hydrates thereof wherein, T1 represents a 4- to 12-membered heterocyclic group containing one or two nitrogen atoms in the ring, which is a monocyclic or bicyclic structure that may have one or more subst ...


22
Nobuyuki Yasuda, Kazuto Yamazaki: Combination drug. Eisai, Townsend And Townsend And Crew, May 4, 2006: US20060094722-A1

The present invention provides pharmaceutical agents comprising a dipeptidyl peptidase IV (DPPIV) inhibitor and a biguanide agent in combination, which enhance the effects of active circulating glucagon-like peptide-1 (GLP-1) and/or active circulating glucagon-like peptide-2 (GLP-2).


23
Koji Sagane, Eiki Takahashi, Kazuto Yamazaki, Turo Oki: Non-human gene-disrupted animal with disrupted Adam11 gene. Eisai R&D Management, Clark & Elbing, December 30, 2010: US20100333216-A1

It is an object of the present invention to provide a non-human gene-disrupted animal with a disrupted ADAM11 gene. According to the present invention, a non-human gene-disrupted animal, wherein either one of or both alleles of an ADAM11 gene are disrupted, is provided.


24
Seiji Yoshikawa, Eita Emori, Fumiyoshi Matsuura, Richard Clark, Hironori Ikuta, Kazunobu Kira, Nobuyuki Yasuda, Tadashi Nagakura, Kazuto Yamazaki: Condensed imidazole derivatives. Eisai R&D Management, Townsend And Townsend And Crew, January 15, 2009: US20090018331-A1

The present invention is related to compounds represented by the following formula, or salts or hydrates thereof wherein, T1 represents a 4- to 12-membered heterocyclic group containing one or two nitrogen atoms in the ring, which is a monocyclic or bicyclic structure that may have one or more subst ...


25